stockrowEli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company (LLY) Return on assets
Eli Lilly and Company's return on assets over the twelve months to 30 September 2026 was 21.0%, down 0.6 percentage points from fiscal 2025 (21.6%). Over the past ten years it has ranged from −0.49% (fiscal 2017) to 21.6% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 21.6% | 6.75 |
| FY2024 | 14.8% | 5.61 |
| FY2023 | 9.23% | (3.48) |
| FY2022 | 12.7% | 1.01 |
| FY2021 | 11.7% | (2.72) |
| FY2020 | 14.4% | (5.58) |
| FY2019 | 20.0% | 12.73 |
| FY2018 | 7.27% | 7.76 |
| FY2017 | −0.49% | (7.85) |
| FY2016 | 7.36% | 0.66 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LLY Eli Lilly and Company | 21.0% |
| AMGN Amgen Inc. compare | 10.1% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| JNJ Johnson & Johnson compare | 8.25% |
| ABBV AbbVie Inc. compare | 7.32% |
| PFE Pfizer Inc. compare | 1.95% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement